Global Liquid Biopsy Market: Analysis By Biomarkers (C-Tumor Cells, C-Tumor DNA, Vesicles), Cancer Type, By Product (Instruments, Reagents), By Region, By Country (2019 Edition): Opportunities and Forecast (2017-2024)

Date: 1 November 2019

According to a research report published by Azoth Analytics in October 2019, the Liquid Biopsy Market was valued at USD 899.55 million in the year 2018. Global liquid biopsy market is expected to grow rapidly on the back of rising incidences of cancer, growing geriatric population, growing government initiatives, and continuous research and development conducted by pharmaceutical manufacturers.  

The Azoth Analytics research report ‘Global Liquid Biopsy Market – 2019 Edition’ has analysed and segmented the market By Cancer Type (Lung, Breast, Colorectal, Prostate, Others), By Circulating Biomarker (circulating tumor cells, ct-DNA, Vesicles) and By Product Type (Reagents, Instruments). The Global Liquid Biopsy Market has been analysed By Region (North America, Europe, Asia Pacific, ROW) and By Country (U.S, Germany, France, Japan) for the actual period of 2017-2018 and the forecast period of 2019-2024.

Growing focus on immunotherapy to cure cancer and shifting trend towards precision medicine along with high per capita healthcare expenditure and rapid adoption of novel diagnostic test by oncologist has led to the majority of the growth of liquid biopsy market. Further, rising awareness for the early detection of cancer and sharp rise in its incidences have contributed to the growth rate of Liquid Biopsy Market. In forecast period, continuous research and development by private manufacturers, government organizations and designated government labs along with growing number of clinical trials in liquid biopsy is anticipated to provide momentum to the market growth. In addition, growing government healthcare expenditure, inclusion of cancer in insurance is expected to fuel the market growth in forecast period. 

By cancer type, application of liquid biopsy in breast cancer is dominating the global market in 2018 and its share is anticipated to rise on the back of growing incidences of breast cancer worldwide as well as large number of benefits associated with its diagnosis of breast cancer. Liquid biopsy offers the opportunity to avoid unnecessary surgeries for the diagnosis and monitoring of disease progression. Amongst the regions, North America accounts for the largest regional share in the global Liquid Biopsy Market. Key factors driving the robust growth rate in North America region include presence of enormous patient base and healthcare companies, high per capita healthcare expenditure and growing government initiatives.